文献速递鼻科

长效植入型糖皮质激素基质治疗慢性鼻窦炎:LANTERN 2期随机对照研究结果

Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study.
PubMed 文献 · Int Forum Allergy Rhinol · 2021-09-17

两种剂量均安全耐受,7500 μg组在4CS和SNOT-22评分上自第8周至第24周较对照组有统计学显著改善,并减少补救治疗使用和筛窦影像学浑浊。

要点

  • LYR-210单次给药可提供长达24周的局部莫米松释放,两种剂量均安全耐受。
  • 7500 μg组自第8周至第24周在4CS和SNOT-22上较对照组有统计学显著改善。
  • 7500 μg组第24周减少补救治疗使用并降低筛窦影像学浑浊。

核心结论

  • LYR-210是首个在手术初治伴或不伴鼻息肉的慢性鼻窦炎患者中单次给药即可获得长达24周获益的植入型鼻窦治疗。

主要发现

  • 两种LYR-210剂量在24周治疗期内均安全且耐受良好。
  • LYR-210显示出快速、持久且剂量依赖性的4CS和SNOT-22症状改善,7500 μg组自第8周至第24周较对照组有统计学显著性。
  • 7500 μg组第24周减少补救治疗使用并降低筛窦影像学浑浊。

关键数值与推荐

  • 患者基于SNOT-22和4项主要慢性鼻窦炎症状7天平均复合评分判定为中重度疾病,诊断经鼻内镜和磁共振成像确认。

临床怎么用

  • 对于手术初治且既往药物治疗控制不佳的慢性鼻窦炎患者,LYR-210 7500 μg单次双侧诊室给药可能提供长达24周的症状改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical steroids are first-line treatment for chronic rhinosinusitis (CRS), but fail to provide adequate symptom control for all patients. Designed for medical treatment failures, LYR-210 is an implantable matrix that locally elutes mometasone furoate to inflamed sinonasal tissue for up to 24 weeks in CRS patients. In an open-label phase 1 study, LYR-210 demonstrated clinically relevant improvement in the 22-item Sino-Nasal Outcome Test (SNOT-22). Safety and efficacy of LYR-210 in CRS were evaluated in the LANTERN Phase 2 study. METHODS: Sixty-seven surgically naive adult CRS patients who were inadequately controlled by previous medical management and seeking an alternative treatment enrolled in a multicenter, blinded, controlled, dose-ranging study. Patients had moderate-to-severe disease based on SNOT-22 and composite 7-day average scores of the 4 cardinal CRS symptoms (4CS), with diagnosis confirmed by nasal endoscopy and magnetic resonance imaging. Patients were randomized (1:1:1) to saline irrigation-only control or bilateral in-office administration of LYR-210 (2500 μg) or LYR-210 (7500 μg). Safety and efficacy were evaluated over 24 weeks. RESULTS: Both LYR-210 doses were safe and well-tolerated over the 24-week treatment period. LYR-210 demonstrated rapid and durable dose-dependent symptom improvement based on 4CS and SNOT-22, with LYR-210 (7500 μg) achieving statistical significance as early as 8 weeks and out to 24 weeks compared with control. LYR-210 (7500 μg) reduced rescue treatment use and radiographic ethmoid opacification at week 24. CONCLUSIONS: LYR-210 is the first implantable sinonasal treatment to achieve up to 24 weeks of benefit from a single administration in surgically naive CRS patients with and without nasal polyps.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Cervin A, Rimmer J, Wrobel A, et al. Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. Int Forum Allergy Rhinol. 2021. PMID: 34534410. doi:10.1002/alr.22883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。